Last reviewed · How we verify
GW679769 (casopitant)
Casopitant is a neurokinin-1 (NK1) receptor antagonist that blocks substance P signaling in the brain to prevent chemotherapy-induced nausea and vomiting.
Casopitant is a neurokinin-1 (NK1) receptor antagonist that blocks substance P signaling in the brain to prevent chemotherapy-induced nausea and vomiting. Used for Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy.
At a glance
| Generic name | GW679769 (casopitant) |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | NK1 receptor antagonist |
| Target | NK1 receptor (neurokinin-1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Casopitant selectively antagonizes the NK1 receptor, which is involved in the emetic pathway triggered by chemotherapy agents. By blocking substance P, a key neurotransmitter in nausea and vomiting pathways, the drug reduces both acute and delayed chemotherapy-induced nausea and vomiting (CINV). It is often used as part of a combination antiemetic regimen with 5-HT3 antagonists and corticosteroids.
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy
Common side effects
- Headache
- Constipation
- Dizziness
- Fatigue
Key clinical trials
- A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting. (PHASE3)
- Cyclophosphamide Drug Interaction Study In Cancer Patients (PHASE1)
- A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults (PHASE1)
- Observational Study Evaluating The Processing Or Breakdown Of GW679769 In Subjects With Hepatic Impairment (PHASE1)
- A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant). (PHASE1)
- Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769] (PHASE1)
- A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy (PHASE3)
- A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GW679769 (casopitant) CI brief — competitive landscape report
- GW679769 (casopitant) updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI